(
out of
327
reviews
)
Specialties
Board Certification
|
National Board of Medical Examiners
|
Patient Rating
Patients describe Dr. Callis Duffin as knowledgeable, caring, and highly skilled in diagnosing and treating dermatologic conditions. Reviewers repeatedly note that she listens carefully, explains issues and treatment options clearly, includes patients in decision making, and that her team is responsive to questions. Many patients credit her with effective long-term management of conditions such as psoriasis and with thorough preventive skin checks, expressing strong confidence and gratitude for her care.
Generated via Patient Reviews
5.0
/5
( out of
327 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Dermatology
-Professor |
|---|---|
| Board Certification |
National Board of Medical Examiners
|
Education history
| Certification | Health Science Leadership Development Program - University of Utah | Certificate |
|---|---|---|
| Graduate Training | Clinical Investigation - University of Utah | M.S.C.I |
| Residency | Dermatology - University of Utah School of Medicine | Resident |
| Fellowship | Dermatology - University of Utah School of Medicine | Fellow |
| Chief Resident | Internal Medicine - Maine Medical Center | Chief Resident |
| Residency | Internal Medicine - Maine Medical Center | Resident |
| Professional Medical | Medicine - University of Washington | M.D. |
| Undergraduate | Biomedical Sciences - Montana State University | B.S. |
Selected Publications
Journal Article
- Blauvelt A, Prussick R, Merola JF, Shahriari M, Cather J, Eakin GS, McCormick Howard L, Lebwohl MG, Armstrong AW, Duffin KC (2025). Clarifying psoriasis disease severity: A position statement from the National Psoriasis Foundation Medical Board. J Am Acad Dermatol.
- Duffin KC, Griffiths CEM, Hoffmann M, Blauvelt A, Balagula Y, Napoli A, Becker B, Jou YM, Dyme R, Hala V, Pinter A, Thai D, Gold LS, Lebwohl M (2025). Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP). JAAD Int, 25, 28-40.
- Gkini MA, Chinchay L, Lindsay CA, Franco M, Castro Ayarza JR, Duffin KC (2025). Diagnosis and Assessment of Psoriasis for the Rheumatologist: A Workshop From the GRAPPA 2024 Annual Meeting. J Rheumatol, 52(Suppl 3), 19-22.
- Ney Z, Ringwood D, Takara M, Frost Z, Conley M, Kean J, Secrest A, Duffin KC, Hopkins Z (2025). Clinical assessment implications from core outcome domain set development exercises in dermatology. J Am Acad Dermatol.
- Armstrong AW, Gondo GC, Merola JF, Roberts AM, Prez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin KC, Fakharzadeh S, Feldman SR, Gelfand JM, Gladman DD, Glick B, Green LJ, Han G, Hawkes JE, Hwang ST, Johnsen N, Kalb RE, Kircik L, Langley RG, Lebwohl MG, Lewitt GM, Maverakis E, Prussick R, Reddy SM, Rosen CF, Scher JU, Siegel EL, Wallace EB, Weinberg JM, Yamauchi PS, Yosipovitch G, Liao W, Remission Workgroup of the National Psoriasis Foundation (2025). Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. JAMA Dermatol.
- Armstrong AW, Lee K, Yee D, Woodbury M, Zundell M, Zagona-Prizio C, Yousif J, Grant C, Shields A, Chou P, Callis Duffin K, Gottlieb AB, Merola JF, Perez-Chada L (2025). Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With Psoriasis. JAMA Dermatol.
- Strober B, Duffin KC, Lebwohl M, Sima A, Janak J, Patel M, Photowala H, Garg V, Bagel J (2023). Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry. J Dermatolog Treat, 35(1), 2287401.
- Gelfand JM, Armstrong AW, Lim HW, Feldman SR, Johnson SM, Claiborne WCC, Kalb RE, Jakus J, Mangold AR, Flowers RH, Bhutani T, Durkin JR, Bagel J, Fretzin S, Sheehan MP, Krell J, Reeder M, Kaffenberger J, Kartono F, Takeshita J, Bridges AM, Fielding E, Nehal US, Schaecher KL, Howard LM, Eakin GS, Bez S, Bishop BE, Fitzsimmons RC Jr, Papadopoulos M, Song WB, Linn KA, Hubbard RA, Shin DB, Callis Duffin K (2025). Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis: The LITE Randomized Clinical Trial. JAMA Dermatol, 160(12), 1320-1328.
- Carroll C, Adalsteinsson JA, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Erratum: Measuring Psoriasis Severity at Home. J Vis Exp, (213).
- Liao W, Armstrong AW, Duffin KC (2024). GRAPPA Debate: Targeted Small Molecules Versus Biologics as First-Line Systemic Therapy After Conventional Therapy for Moderate-to-Severe Psoriasis. J Rheumatol, 51(Suppl 2), 89-92.
- Carroll C, Aalsteinsson J, Prouty M, Duffin KC, Krueger GG, Walsh JA, Feng BJ (2024). Measuring Psoriasis Severity at Home. J Vis Exp, (205).
- Chat VS, Ellebrecht CT, Kingston P, Bell S, Gondo G, Cordoro KM, Desai SR, Duffin KC, Feldman SR, Garg A, Gelfand JM, Gladman D, Green LJ, Gudjonsson J, Han G, Hawkes JE, Kircik L, Koo J, Langley R, Lebwohl M, Michael Lewitt G, Liao W, Martin G, Orbai AM, Reddy SM, Richardson V, Ritchlin CT, Schwartzman S, Siegel EL, Van Voorhees AS, Wallace EB, Weinberg JM, Winthrop KL, Yamauchi P, Armstrong AW (2024). Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol.
- Garg A, Noe MH, Anadkat MJ, Armstrong A, Bhutani T, Farberg A, Han G, Hawkes JE, Lebwohl M, Rekhtman S, Song EJ, Strunk A, Duffin KC (2023). Development of the Generalized Pustular Psoriasis Clinical Assessment Tool. J Am Acad Dermatol, 90(1), 192-195.
- Rhoads JLW, Malatestinic WN, Burge R, Ganz ML, Duffin KC (2023). Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data. J Psoriasis Psoriatic Arthritis, 9(1), 5-15.
- Strober B, Ferris L, Duffin KC, Janak JC, Sima AP, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A (2023). Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol.
- Walsh JA, Carroll C, Callis Duffin K, Wang J, Krueger GG, Feng BJ (2023). PAPRIKA: A Question Bank for Assessing Psoriatic Arthritis Risk in Individuals of Diverse Ancestries. Arthritis Care Res (Hoboken), 76(3), 421-425.
- Callis Duffin K, Hwang ST, Krueger JG (2023). Advances and Controversies in Our Understanding of Guttate and Plaque Psoriasis. J Rheumatol.
- Ng BCK, Jadon D, Adebajo A, Ayan G, Callis Duffin K, Chandran V, Coates LC, DAgostino MA, de Vlam K, Deodhar A, Eder L, Garg A, Gladman DD, Goel N, Gottlieb AB, Husni ME, Katz A, Kavanaugh A, Lubrano E, Mease PJ, Merola JF, Nash P, Ogdie A, Pennington SR, Perez-Chada LM, Proft F, Rosen CF, Savage L, Goldenstein-Schainberg C, Siebert S, Soriano ER, Steinkoenig I, Tillett W, Armstrong AW, FitzGerald O (2023). Proceedings of the GRAPPA 2022 Executive Retreat. J Rheumatol.
- Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K (2023). The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Adv Ther, 40(5), 2493-2508.
- Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Alexander AN, Tang M, Thoma C, Duffin KC (2023). The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity. Br J Dermatol.
- Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K (2023). Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb), 13(2), 629-640.
- Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K (2023). Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb), 13(2), 487-504.
- Gold LS, Papp K, Pariser D, Bhatia N, Sofen H, Albrecht L, Gooderham M, Duffin KC, Chen M, Paris M, Cheng S, Picard H, Wang Y, Green L (2023). Efficacy and safety of apremilast in patients with mild-to-moderate psoriasis up to 32 weeks: Results from the extension phase of the randomized, phase 3 ADVANCE trial. J Am Acad Dermatol, 88(2), 430-433.
- Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernndez-vila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, OSullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A, Campanholo CB, Fitzgerald O, Gladman D, Helliwell P, Husni ME, Laheru D, Leung YY, Mazzuoccolo LD, Mease PJ, Ogdie A, Palominos PE (2022). Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 (Nature Reviews Rheumatology, (2022), 18, 8, (465-479), 10.1038/s41584-022-00798-0). Nat Rev Rheumatol, 18(12), 734.
- Hopkins ZH, Kuceki G, Taliercio VL, Snyder AM, Stoddard GJ, Duffin KC, Hess R, Secrest AM (2022). Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance. Arch Dermatol Res, 315(5), 1151-1159.
- Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, Chau J, Eder L, Fernndez-vila DG, FitzGerald O, Garg A, Gladman DD, Goel N, Helliwell PS, Husni ME, Jadon DR, Katz A, Laheru D, Latella J, Leung YY, Lindsay C, Lubrano E, Mazzuoccolo LD, Mease PJ, OSullivan D, Ogdie A, Olsder W, Palominos PE, Schick L, Steinkoenig I, de Wit M, van der Windt DA, Kavanaugh A, Campanholo CB, Fitzgerald O, Gladman D, Helliwell P, Husni ME, Laheru D, Leung YY, Lubrano E, Mazzuoccolo LD, Mease PJ, Ogdie A, Palominos PE (2022). Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol, 18(8), 465-479.
- Takeshita J, Chau J, Duffin KC, Goel N (2022). Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases. J Rheumatol, 49(6), 48-51.
- Armstrong AW, Reddy RM, FitzGerald O, Duffin KC, Helliwell PS, Mease PJ, Kavanaugh A, Merola JF, Tillet W, Wit Md (2022). 2021 GRAPPA Meet the Experts Session: A Summary of Presentations. J Rheumatol, 49(6), 32-36.
- Duffin KC, Gladman DD, Goel N, Gottlieb AB, FitzGerald O, McFarland LV (2022). Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol, 49(6), 1-3.
- Ogdie A, Lindsay CA, Mease PJ, Duffin KC, Rosen CF, Siebert S (2022). Challenges in the Diagnosis and Assessment of Psoriatic Arthritis. J Rheumatol, 49(6), 64-67.
- Noe MH, Wan MT, Mostaghimi A, Gelfand JM, Agnihothri R, Armstrong AW, Bhutani T, Bridges A, Brownstone N, Butt M, Duffin KPC, Carr C, Creadore A, Deniro KL, Desai S, Dominguez AR, Duffy EK, Fairley JA, Femia A, Gudjonsson JE, Kaffenberger JA, Katz KL, Le ST, Martinez E, Maverakis E, Myers B, Naik HB, Nelson CA, Ortega-Loayza AG, Plovanich ME, Rangel LK, Ravi V, Reddy VD, Saleh JZ, Kirby JS, Sandhu JK, Shakshouk H, Shields BE, Sharif-Sidi Z, Smith J, Steahr A, Toussi A, Wanat KA, Wang B, Wei BM, Weinhammer A, Worswick SD, Yang A (2022). Evaluation of a Case Series of Patients with Generalized Pustular Psoriasis in the United States. JAMA Dermatol, 158(1), 73-78.
- Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2022). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119.
- Stein Gold L, Papp K, Pariser D, Green L, Bhatia N, Sofen H, Albrecht L, Gooderham M, Chen M, Paris M, Wang Y, Callis Duffin K (2022). Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 86(1), 77-85.
- Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry. Dermatol Ther (Heidelb), 12(1), 97-119.
- Taliercio VL, Snyder AM, Biggs AM, Kean J, Hess R, Duffin KC, Cizik AM, Secrest AM (2021). Clinicians' perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study. Qual Life Res, 31(6), 1719-1725.
- Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Duffin KC, Krueger GG, Feng BJ (2021). Psoriasis Characteristics for the Early Detection of Psoriatic Arthritis. J Rheumatol, 48(10), 1559-1565.
- Duffin KC, Gottlieb AB, OSullivan D, Gladman DD, McFarland LV (2021). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl, 97, 1-3.
- Mease PJ, Calabrese LH, Duffin KC, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. J Rheumatol Suppl, 97, 24-29.
- Duffin KC, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola JF, Chau J, Kishimoto M, Furer V, Helliwell PS (2021). Pustular Psoriasis and Associated Musculoskeletal Disorders. J Rheumatol Suppl, 97, 34-38.
- Callis Duffin K, Bachelez H, Mease PJ, Rosen C, Garg A, Zudak E, Elkayam O, Merola J, Chau J, Kishimoto M, Furer V, Helliwell PS (2021). Pustular Psoriasis and Associated Musculoskeletal Disorders. J Rheumatol.
- Mease PJ, Calabrese LH, Callis Duffin K, Haberman RH, Firmino R, Scher JU, Schick L, Winthrop K, Merola JF (2021). Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. J Rheumatol.
- Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (2021). Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology, 237(2), 151-157.
- Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Callis Duffin K, Gladman DD (2021). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. J Rheumatol.
- Callis Duffin K, Gottlieb AB, OSullivan D, Gladman DD, McFarland LV (2021). Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol.
- Taliercio V, Langner AU, Secrest AM, Duffin KC (2021). Assessing psoriasis severity: psychometric validation of overall physician global assessment (OPGA). J Am Acad Dermatol, 86(3), 637-638.
- Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M (2021). Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology, 237(1), 46-55.
- Carlisle RP, Flint ND, Hopkins ZH, Eliason MJ, Duffin KC, Secrest AM (2020). Administrative Burden and Costs of Prior Authorizations in a Dermatology Department. JAMA Dermatol, 156(10), 1074-1078.
- Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tyring SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta NN (2020). A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). J Invest Dermatol, 140(9), 1784-1793.e2.
- Taliercio V, Langner AU, Secrest AM, Duffin KC (2020). Research Letter Measuring quality in psoriasis: early experiences with the MIPS 410 quality measure-cross sectional study. J Am Acad Dermatol, 88(5), 1119-1121.
- Waxman R, Stober C, Jadon DR, Orbai AM, Chandran V, Ogdie A, Pennington SR, De Wit M, OSullivan D, Mease PJ, Armstrong AW, Callis Duffin K, Helliwell PS, Van Mens LJJ, Ritchlin CT, FitzGerald O (2020). Proceedings of the 2019 grappa collaborative research network meeting. J Rheumatol, 96, 25-30.
- Leung YY, Tillett W, Orbai AM, Ogdie A, Eder L, Coates LC, Holland R, Antony A, Goel N, Mease PJ, Strand V, FitzGerald O, De Wit M, Lindsay CA, Duffin KC, Gladman DD (2020). The grappa-omeract working group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates. J Rheumatol, 96, 46-49.
- Coates LC, Merola JF, Grieb SM, Mease PJ, Duffin KC (2020). Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol, 96, 31-35.
- Duffin KC, Gladman DD, Goel N, Gottlieb AB (2020). Prologue: 2019 annual meeting of the group for research and assessment of psoriasis and psoriatic arthritis (grappa). J Rheumatol, 96, 1-3.
- Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, Vender R, Lomaga MA, Delorme I, Hong CH, Langley RL, Albrecht L, Guenther L, Maari C, Papp K, Singh Ohson KK, Barber K, Lynde C, Gupta A, Rosoph L, Gauthier JS, Gooderham M, Wasel N, Raman M, Wiseman M, Greenstein D, Jarell A, Moon C, Clark L, Jazayeri SS, Bukhalo M, Moore A, Hamilton TK, Gewirtzman A, Hazan L, Crowley J, Teller C, Zirwas M, Smith SR, Christine Lee M, Tyring S, Lee P, Dhawan S, Leonardi C, Jesus APD, McFalda W, Frankel E, Yamauchi P, Fretzin S, Serrao R, Schlesinger T, Gottlieb S, Jenkin P, Gharib R, Davis S, Nami N, Draelos ZD, Godwin L, Owen C, Landis M, Abramovits W, Sanchez-Rivera S, Van Voorhees A, Fivenson D, Kerdel F, Forman SB, Weinberg J, Gonzalez-Chavez J, Boyce B, Stein-Gold L, Hudson C, Brown C, Coggi J, Feser C, Forconi R, Johnson S, McCune M, Green L, Madkan V, Shipp DM, Gordon KB, Waibel J, Soto-Raices O, Cather J, Miller S, Scott J, Young D, Kaffenberger J, Yokum K (2020). A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol, 182(6), 1348-1358.
- Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (2020). Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. Am J Clin Dermatol, 21(3), 323-338.
- Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF (2019). Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. J Am Acad Dermatol, 82(1), 54-61.
- Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM (2019). Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. J Am Acad Dermatol, 81(4), 923-930.
- Strober B, van de Kerkhof PCM, Callis Duffin K, Poulin Y, Warren RB, de la Cruz C, van der Walt JM, Stolshek BS, Martin ML, de Carvalho AVE (2019). Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. Am J Clin Dermatol, 20(5), 699-709.
- Perez-Chada L, Taliercio VL, Gottlieb A, Van Beek M, Duffin KC, Reeder M, Merola JF, Swerlick RA (2019). Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. J Am Acad Dermatol, 88(1), 86-93.
- Callis Duffin K, Bushmakin AG, Cappelleri JC, Mallbris L, Mamolo C (2019). A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies. BMC Dermatol, 19(1), 8.
- Callis Duffin K, Gladman DD, Gottlieb AB, Goel N (2019). Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol Suppl, 95, 1-3.
- Jadon DR, Chandran V, Ogdie A, Pennington SR, Stober C, Gladman DD, de Wit M, OSullivan D, Mease P, Armstrong AW, Callis Duffin K, Magee C, Helliwell P, Ritchlin CT, FitzGerald O (2019). Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. J Rheumatol Suppl, 95, 11-19.
- Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W (2019). The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. J Rheumatol Suppl, 95, 33-37.
- Duffin KC Md Ms (2015). Identifying and Managing Complications and Comorbidities in Patients With Psoriasis. Semin Cutan Med Surg, 34(2 Suppl), S30-3.
- Duffin KC Md Ms (2015). Screening and Monitoring Before and During Systemic Therapy: Recommendations for Patients With Psoriasis. Semin Cutan Med Surg, 34(2 Suppl), S40-2.
- Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC (2013). Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol, 149(5), 577-82.
- Walsh JA, Callis Duffin K, Krueger GG, Clegg DO (2013). Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol, 40(3), 287-93.
- Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM (2013). Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol, 68(1), 64-72.
- Jordan CT, Cao L, Roberson ED, Duan S, Helms CA, Nair RP, Duffin KC, Stuart PE, Goldgar D, Hayashi G, Olfson EH, Feng BJ, Pullinger CR, Kane JP, Wise CA, Goldbach-Mansky R, Lowes MA, Peddle L, Chandran V, Liao W, Rahman P, Krueger GG, Gladman D, Elder JT, Menter A, Bowcock AM (2012). Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet, 90(5), 796-808.
- Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS (2012). Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol, 148(4), 487-94.
- Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr (2012). Consensus guidelines for the management of plaque psoriasis. Arch Dermatol, 148(1), 95-102.
- Wong B, Machan M, Krueger GG, Callis Duffin K (10/01/11). Increased Prevalence of Sleep Disorders and Medical Comorbidities in Psoriatic Arthritis Patients Compared with Patients With and Without Psoriasis. Psoriasis Forum, 17(3), 209-215.
- Callis Duffin K, Mease PJ (2011). Psoriasis and Psoriatic Arthritis Video Project 2010: a report from the GRAPPA annual meeting. J Rheumatol, 38(3), 562-3.
- Narayanan S, Callis-Duffin K, Batten J, Agarwal N (2010). Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci, 339(6), 580-1.
- Duffin KC, Freeny IC, Schrodi SJ, Wong B, Feng BJ, Soltani-Arabshahi R, Rakkhit T, Goldgar DE, Krueger GG (2009). Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. J Invest Dermatol, 129(12), 2777-83.
- Feng BJ, Sun LD, Soltani-Arabshahi R, Bowcock AM, Nair RP, Stuart P, Elder JT, Schrodi SJ, Begovich AB, Abecasis GR, Zhang XJ, Callis-Duffin KP, Krueger GG, Goldgar DE (2009). Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet, 5(8), e1000606.
- Nair RP, Ding J, Duffin KC, Helms C, Voorhees JJ, Krueger GG, Bowcock AM, Abeasis GR, Elder JT (2009). Psoriasis bench to bedside: genetics meets immunology. Arch Dermatol, 145(4), 462-4.
- Callis Duffin K, Wong B, Horn EJ, Krueger GG (2009). Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol, 60(4), 604-8.
- Grande-Sarpa H, Callis Duffin KP, Florell SR (2008). Onychodystrophy and tumor-stage mycosis fungoides confined to a single digit: report of a case and review of nail findings in cutaneous T-cell lymphoma. J Am Acad Dermatol, 59(1), 154-7.
Review
- Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola JF (2025). Psoriasis. [Review]. Nat Rev Dis Primers, 11(1), 45.
- Ball GD, Hamade H, Gottlieb AB, Kirby B, Duffin KC (2024). GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis? [Review]. J Rheumatol, 51(Suppl 2), 39-42.
- Duffin KC, Thio HB, Helliwell PS (2024). Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis, Palmoplantar Pustulosis, and Neutrophilic Dermatoses: A GRAPPA 2023 Annual Meeting Update. [Review]. J Rheumatol, 51(Suppl 2), 77-79.
- Choon SE, Van De Kerkhof P, Gudjonsson JE, De La Cruz C, Barker J, Morita A, Romiti R, Affandi AM, Asawanonda P, Burden AD, Gonzalez C, Marrakchi S, Mowla MR, Okubo Y, Oon HH, Terui T, Tsai TF, Callis-Duffin K, Fujita H, Jo SJ, Merola J, Mrowietz U, Puig L, Thai D, Velsquez M, Augustin M, El Sayed M, Navarini AA, Pink A, Prinz J, Turki H, Magalhes R, Capon F, Bachelez H (2024). International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis from the International Psoriasis Council. [Review]. JAMA Dermatol, 160(7), 758-768.
- Duffin KC, Mazzuoccolo LD, Cura MJ, Esposito M, Fernandez AP, Gisondi P, Giunta A, Hillary T, Piaserico S, Solomon JA, Merola JF (2022). Treatment of Psoriasis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. [Review]. J Rheumatol, 50(1), 131-143.
- deShazo RA, Secrest AM, Armstrong AW, Duffin KC (2020). Addressing Hypertension in Patients With Psoriasis: Review and Recommendations. [Review]. J Psoriasis Psoriatic Arthritis.
- Salame N, Torres J, Sandhu J, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW (2018). Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). [Review]. Dermatology, 234(3-4), 112-119.
Book Chapter
- DeShazo R (2014). Topical Agents. In DeShazo R. (Ed.), Moderate to Severe Psoriasis Fourth Edition (pp. 41-65).
Conference Proceedings
- Duffin KC, Mease PJ (2015). Psoriasis and psoriatic arthritis educational initiatives: An update from the 2014 GRAPPA annual meeting. In Duffin KC|Mease PJ (Ed.), J Rheumatol, 42(6), 1056-1058.
Editorial
- Hopkins ZH, Perez Chada LM, Duffin KC (2023). Defining what matters through core outcomes set development: Uniting stakeholder perspectives, empowering patient voices. Br J Dermatol.
Letter
- Romagosa R, Kerdel F, Shah N, Krueger G, Callis K (2002). Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive disease [6] [Letter to the editor]. J Am Acad Dermatol, 47(6), 970-972.
Other
- Leung YY, Orbai AM, Tillett W, Ogdie A, Eder L, Goel N, Hojgaard P, Holland R, Mathew AJ, Lindsay CA, Antony A, Chau J, Christensen R, Coates LC, Mease PJ, Strand V, FitzGerald O, de Wit M, Duffin KC, Gladman DD (2021). Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. J Rheumatol Suppl (97, pp. 60-63). Canada.
News & Podcasts
News
- Chair of Department of Dermatology Named at University of Utah
- Patrol Your Moles: What They Mean for Your Skin Health
- Kristina Callis Duffin, MD, MS, appointed Interim Dean of the Spencer Fox Eccles School of Medicine at the University of Utah
- Kristina Callis Duffin, MD, MS, Named Dean of the Spencer Fox Eccles School of Medicine at the University of Utah
I've been treated by Dr Duffin for several years now. I find her engaged, friendly, and very professional¿.if she was any different, I would not still be her patient.
The U Health people are ALL so caring and listen to your concerns & questions with care & helpful in any way they can! If your looking for dermatology help, we recommend their office for tender, loving, care!!!!
Dr. Callis Duffin is an excellent provider. She's personable and explains things well. Totally relaxed in her care.
She gave me the first correct diagnosis and got me on a plan that worked. I even moved away to Florida and her care was so good I would fly back to Utah for treatment. She is a brilliant Doctor and an honor to have her care.
Highly recommend Dr Callis Diffin. Such a caring and knowledgeable physician.
The best
Dr Callis is amazing. Always spot on.
I feel very fortunate to have Dr. Callis as my dermatologist.
Dr. Callis Duffin is very thorough and is excellent at explaining particular issues. I feel great confidence in her care.
Dr Kristina has been caring for me for about 10 years now! She's always been great in taking care of my psoriasis problems.
Kind and knowledgeable care provider
Dr callis is the best.
Dr Callis listened to my concerns and expressed positive suggestions as to what options I have to continue her treatment for my psoriasis condition.
I have seen Dr Callis Duffin for several years and have ALWAYS had a positive experience! She's the best!!
Very personable and is great to work with. No anxiety about having to deal with a crusty robot.
Dr Callis-Duffin has been my doctor for over 30 years. She is excellent!
I trust Dr Callis-Duffin completely with my dermatology needs. She found a cancerous mole on my back that I would have never seen. I feel that she saved my life!! Now I come for yearly checks and she is very thorough in making sure I'm healthy!
Very knowledgeable and considerate of how treatment would affect me
Dr Callis Duffin was extremely knowledgeable in the treatment of psoriasis. I went to her to get a second opinion on my disease, she concurred with my physician in Billings, MT that we were on the right track in our treatment regimen. She also let me know that if treatment ceased to work efficiently that there are other medications available. I appreciated her taking time to answer my questions and give me a handout with information pertaining to different groups of medications.
I have been seeing Dr. Callis Duffin for a yearly skin check for over 20 years. She is always thorough, courteous, professional and explains things in an understandable way.
Awesome
She is the BEST in her field & we hope to be able to continue with her for many more years, if you donÕt get it we REALLY like her!!!!
Skilled and with great expertise she and her team treated our skin and conditions perfectly.
Excellent provider. Kind, personable, includes patient in decision making.
The first time meeting Dr Callis Duffin. She was friendly, kind and very professional explaining my condition, listening to my questions, and going over my treatment plan.
She's professional but most important she's friendly, easy to talk to. She explains everything as she's doing it, includes you in her plan of care and answers any questions you have.
I can't say enough good things about Dr. Callis Duffin. I feel very fortunate to have her as my doctor. She was the first one to really take my psoriasis seriously and work to find an effective solution.
She is the best!
Dr Callis is a great doctor. always listens to my concerns. Thank you
Dr. Callis listens to her patients needs. She understands psoriasis greatly and her and her team are very responsive to questions and inquiries.
Dr. Duffin is always friendly and knowledgeable. I feel confident that I'm getting great care.
Dr. Calais Duffin is without a doubt the best dermatologist for me. Her expertise is unmatched, and I have complete confidence in her abilities.